Exponent, Inc. — Form 10-Q Summary
Reporting period: The filing covers the three months ended April 1, 2016, compared with the three months ended April 3, 2015. This differs from the request metadata, which identifies 2015 Q1. The financial statements are unaudited.
Business context and financial results
Exponent provides multidisciplinary engineering and scientific consulting services. Amounts below are in millions of dollars except per-share data and percentages.
| Metric | Q1 2016 | Q1 2015 | Change / context |
|---|---|---|---|
| Revenue | $83.2 | $80.3 | +3.6% |
| Revenue before reimbursements | $79.0 | $76.1 | +3.7% |
| Operating income | $16.4 | $15.0 | +9.4%; operating margin on revenue before reimbursements was approximately 20.8% vs. 19.7% |
| Net income | $15.4 | $10.3 | Increase primarily reflects a $4.461 million share-based-payment tax benefit |
| Diluted EPS | $0.56 | $0.38 | Excluding the tax benefit, Q1 2016 diluted EPS was $0.40 |
| Operating cash flow | $0.3 | $1.7 | Lower year over year |
| Cash, equivalents and short-term investments | $155.0 | Not provided for prior-year quarter | $171.6 at January 1, 2016 |
| Cash dividends declared per share | $0.18 | $0.15 | Next $0.18 dividend declared for payment June 24, 2016, subject to stated record date |
Operating expenses were $66.7 million versus $65.3 million. EBITDA was $19.0 million, or 24.1% of revenue before reimbursements, compared with $18.4 million, or 24.2%. The filing lists no borrowings or debt balance. Current assets were $261.7 million and current liabilities $54.7 million at April 1, 2016; total equity was $272.5 million.
Material changes and operating trends
- Engineering and Other Scientific revenue increased 8.4% to $64.8 million; segment operating income rose to $21.1 million from $19.2 million.
- Environmental and Health revenue declined 10.5% to $18.3 million; segment operating income fell to $5.2 million from $6.5 million. Management attributed the decline to a major investigation that ended in July 2015 and weaker demand in health centers.
- Overall billable hours rose 1% to 295,000, while utilization declined to 74% from 75%. Technical FTEs increased 3% to 768.
- Compensation expense rose 1.8% and other operating expenses rose 7.3%; management cited hiring, salary increases, facilities and infrastructure investment. Other income declined 36.5%, mainly due to a smaller increase in deferred-compensation plan asset values.
- Cash and equivalents decreased $27.2 million during the quarter. Financing cash outflows included $7.6 million of payroll taxes on restricted stock units, $3.5 million of share repurchases and $4.6 million of dividends. Investing outflows included $12.0 million of net short-term investment purchases and $1.5 million of capital expenditures.
Outlook, accounting items and risks
- Management reported good demand across a diverse client base, including proactive work in consumer electronics and medical devices, but gave no quantified revenue or earnings guidance. It expects compensation, other operating and general and administrative expenses to increase as it selectively hires and invests in infrastructure and business development.
- Exponent early adopted ASU 2016-09 prospectively. The resulting $4.461 million excess tax benefit reduced reported income taxes and raised reported net income and diluted EPS; excluding it, net income was $10.889 million and diluted EPS $0.40. The company also elected to recognize share-award forfeitures when they occur.
- Management said existing cash and investments should meet working-capital, capital expenditure, repurchase, dividend and other liquidity needs for at least 12 months. It expects to continue dividends and may repurchase shares or pursue complementary acquisitions.
- Risks cited include demand changes, engagement timing, pricing competition, lack of backlog, retaining key employees, tort reform, government regulation, claims and foreign-exchange movements. The company does not hedge foreign currency exposures; a 10% move in relevant local currency against nonfunctional-currency net assets could produce an estimated $0.23 million gain or loss.
- Legal claims arise in the ordinary course; management did not expect them to materially affect financial condition, results or liquidity, but outcomes remain uncertain. The filing reports no material legal proceedings and no material changes to previously disclosed risk factors.
- The company is evaluating new revenue-recognition and lease standards. It expected the lease standard to materially increase reported assets and liabilities when adopted.
Investor verification priorities
- Confirm the filing period: the document is for Q1 2016, not Q1 2015 as stated in the request metadata.
- Separate underlying earnings growth from the one-time $4.461 million tax benefit when assessing net income and EPS.
- Track Environmental and Health utilization and revenue following the completed investigation, alongside growth in Engineering and Other Scientific.
- Assess operating cash conversion and working-capital movements, particularly receivables and accrued payroll, against the company’s capital returns.
- Review the extent of deferred-compensation obligations: the filing reports $46.2 million of deferred compensation liabilities and $37.4 million of related plan assets on the balance sheet.